June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Estimating the cost of visual impairment: initial results.
Author Affiliations & Notes
  • Ana Patricia Marques
    Health Policy and Management Dept, Escola Nacional Saude Publica - Univ Nova, Lisboa, Portugal
  • Antonio Filipe Macedo
    Vision Rehabilitation Lab., Centre/Department of Physics and Optometry, Braga, Portugal
  • Amandio A Rocha-Sousa
    Department of Senses Organs, Faculty of Medicine/Unversity of Porto, Porto, Portugal
  • Antonio M G Baptista
    Vision Rehabilitation Lab., Centre/Department of Physics and Optometry, Braga, Portugal
  • Gary S Rubin
    Visual Neuroscience, UCL-Institute of Ophthalmology, London, United Kingdom
  • Joel Monteiro
    Ophthalmology, Centro Hospitalar do Alto Ave, Guimarães, Portugal
  • Laura Hernández_Moreno
    Vision Rehabilitation Lab., Centre/Department of Physics and Optometry, Braga, Portugal
  • Joana Cima
    Health Policy and Management Dept, Escola Nacional Saude Publica - Univ Nova, Lisboa, Portugal
  • Rui Santana
    Health Policy and Management Dept, Escola Nacional Saude Publica - Univ Nova, Lisboa, Portugal
  • Footnotes
    Commercial Relationships Ana Marques, None; Antonio Macedo, None; Amandio Rocha-Sousa, None; Antonio Baptista, None; Gary Rubin, None; Joel Monteiro, None; Laura Hernández_Moreno, None; Joana Cima, None; Rui Santana, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2134. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ana Patricia Marques, Antonio Filipe Macedo, Amandio A Rocha-Sousa, Antonio M G Baptista, Gary S Rubin, Joel Monteiro, Laura Hernández_Moreno, Joana Cima, Rui Santana, PORTUGUESE VISUAL IMPAIRMENT STUDY GROUP (PORVIS-GROUP); Estimating the cost of visual impairment: initial results.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2134.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Vision loss can have a substantial human and economic impact on individuals and society that include disability, loss of productivity and reduction in quality of life. The purpose of this study was to estimate economic burden of visual impairment in Portugal.

Methods: A prevalence-based cost of illness approach was adopted to estimate costs of vision impairment. We estimated direct medical costs and indirect economic costs. Direct medical hospital costs were determined using a bottom up approach. For those meeting the inclusion criteria (visual acuity of 20/40 or 0.5decimal or worse in the better eye and/or visual field of less than 20deg) we estimated direct costs by collecting information from administrative records that included: physician’s office visits, emergency and outpatient visits. We developed a survey based in parts of the annotated cost questionnaire-HERU Discussion Paper N.03/01 (UK Working Party on Patient Costs) and the Service Receipt Inventory-European Version. Using the questionnaire that we developed, in face-to-face interviews, we collect direct medical expenditures supported by patients that included: costs with medical prescriptions, low vision aids and devices. With the same questionnaire we collected information for indirect costs calculations. Indirect costs were calculated by estimating the value of productivity losses including employment participation, absenteeism and caregiver costs.

Results: Results presented here correspond to 442 patients that met the inclusion criteria. The four main causes of visual impairment in this sample were Diabetic Retinopathy, Cataract, Glaucoma and Age-related macular degeneration. Direct medical hospital costs were accountable for 12% of total costs calculated. Patient expenditures represented 25% of expenses with visual impairment and indirect costs corresponded to 63% of the total. From this data we estimated that the average annual direct cost per patient with VI was 958 euro and average annual indirect cost was 1655 euro.

Conclusions: With the instruments and methodology that was adopted we were able quantify direct medical hospital costs as well as indirect costs of visual impairment. Results of this study show that more than half of the costs with VI are indirect. This highlights that particular attention should be given to costs that arise for individuals with vision loss.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×